EHA 2021| Daratumumab plus lenalidomide and dexamethasone (D-Rd) shows overall survival benefit in elderly patients with transplant-ineligible newly diagnosed myelomaConferences, MyelomaJune 14, 2021
EHA 2021 | Daratumumab maintenance improves Progression-Free Survival (PFS) after autologous stem cell transplantation in myelomaConferences, MyelomaJune 13, 2021
EHA 2021 | Patient preferences in myeloma, a qualitative multinational study in myelomaConferences, MyelomaJune 11, 2021
European Commission approves the second indication of isatuximab for relapsed multiple myelomaAccess, MyelomaApril 19, 2021
Selinexor receives Conditional Marketing Authorisation in Europe for the treatment of relapsed and or refractory myeloma patientsAccess, MyelomaMarch 30, 2021
